Search through
Bempedoic Acid is an oral, once-daily ATP-citrate lyase inhibitor and prodrug activated by hepatic ACSVL1 enzyme. By interrupting early cholesterol biosynthesis, it lowers LDL-C and is indicated for patients intolerant to statins or requiring additional LDL-C reduction. Bempedoic Acid manufactured on the purpose of Cardiovascular Therapeutic Agent end usage. It is also called as ETC-1002, acido bempedoico, Nexletol by suppliers.
Bempedoic Acid is an oral, once-daily ATP-citrate lyase inhibitor and prodrug activated by hepatic ACSVL1 enzyme. By interrupting early cholesterol biosynthesis, it lowers LDL-C and is indicated for patients intolerant to statins or requiring additional LDL-C reduction. Bempedoic Acid manufactured on the purpose of Cardiovascular Therapeutic Agent end usage. It is also called as ETC-1002, acido bempedoico, Nexletol by suppliers.
.3d8f8f41.svg)
Pharmaceutical
.3556d45a.svg)
Pharmaceutical Actives & Precursors
Active Pharmaceutical Ingredients (APIs)
.7767eb0f.png)
Chemical Properties & Specifications
Low systemic toxicity; non-carcinogenic; avoid ingestion. Not classified as hazardous under standard lab handling.
Use standard lab PPE.
Non-carcinogenic, non-mutagenic (per ICH S2(R1))
Serves as a prodrug that inhibits ACL in hepatocytes, effectively reducing hepatic cholesterol and LDL-C levels.
Used in the formulation of Nexletol® and fixed-dose combinations (e.g., with ezetimibe).
R&D and commercial production of lipid-lowering pharmaceuticals, particularly for patients unable to tolerate statins.
Requires hepatic ACSVL1 enzyme-confers liver-specific activity, reducing muscle toxicity
Inhibits ACL and activates AMPK in vitro- may confer anti-inflammatory effects
Weak inhibition of OATPs and OATs; no CYP450 involvement minimizes interaction risk
Low solubility, high permeability critical for formulation strategies
Store at 2–8 °C in a tightly sealed container; protect from moisture.